Press release

Validation of the ZENEO® Midazolam clinical batch

Launch of operations related to the bioequivalence study
Triggering of a milestone on the DESITIN agreement

Dijon, 2 December 2021

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces the compliance of the clinical batch for the ZENEO® Midazolam 10mg bioequivalence study (epileptic seizures).

Patrick Alexandre, President of the Crossject Management Board, said: *"The extensive testing performed on the ZENEO® Midazolam clinical batch for the bioequivalence study met all control criteria. This step allows us not only to launch operations related to the clinical bioequivalence study, but also to record a milestone in our contractual relationship with DESITIN.*[1] *We are pleased with the news, which testifies to the quality of our production facilities and marks a new step towards the marketing of our ZENEO® devices."*

The analysis of the results of the tests performed on the ZENEO® Midazolam 10mg clinical batch validates its compliance with the specifications. This step allows the launch of all activities related to the clinical bioequivalence study: anonymised packaging, export of therapeutic units, recruitment of volunteers, etc. The study's purpose is to demonstrate bioequivalence between an intramuscular injection administered by a syringe fitted with a needle and that administered with ZENEO®.

It also represents an important development milestone in Crossject's contractual relationship with DESITIN, with which it entered into a commercial agreement on ZENEO® Midazolam for Germany in 2019. Under the terms of the contract, this development milestone triggers a payment of €0.5 million.

[1] See press release dated 18 June 2019

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)3 80 43 54 89
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.